@article{65a5e7734bd744d285ab70432ccf5559,
title = "Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study",
abstract = "This analysis represents the longest-term follow-up for patients with acute myeloid leukemia (AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in an open-label, non-randomized, multicenter phase 1b trial of venetoclax with azacitidine (AZA; 75 mg/m2; days 1-7) or decitabine (DEC; 20 mg/m2; days 1-5). Endpoints included safety, response rates (complete remission [CR], CR with incomplete blood count recovery [CRi]), response duration and overall survival (OS). The median follow-up time was 29 and 40 months for patients treated with venetoclax plus AZA and DEC combinations, respectively. Key Grade ≥ 3 AEs (AZA and DEC) were febrile neutropenia (39% and 65%), anemia (30% and 26%), thrombocytopenia (25% and 23%), and neutropenia (20% and 10%). The CR/CRi rate was 71% for venetoclax plus AZA and 74% for venetoclax plus DEC. The median duration of CR/CRi was 21.9 months and 15.0 months, and the median OS was 16.4 months and 16.2 months, for venetoclax plus AZA and DEC, respectively. These results support venetoclax plus hypomethylating agents as highly effective frontline AML therapies for patients unfit for intensive chemotherapy.",
author = "Pollyea, {Daniel A.} and Keith Pratz and Anthony Letai and Jonas, {Brian A.} and Wei, {Andrew H.} and Vinod Pullarkat and Marina Konopleva and Thirman, {Michael J.} and Martha Arellano and Becker, {Pamela S.} and Brenda Chyla and Hong, {Wan Jen} and Qi Jiang and Jalaja Potluri and DiNardo, {Courtney D.}",
note = "Funding Information: : Research funding from AbbVie/Genentech, Agios, Celgene, Daiichi Sankyo, Millennium, Novartis; served as consultant for Agios; advisory board member for AbbVie, Agios, Bayer, Celgene, Karyopharm, and Medimmune. C DiNardo Funding Information: : Research funding from AbbVie, Agios, Daiichi Sankyo, Millennium; advisory board member for AbbVie, Astellas, and Boston BioMedical. K Pratz Funding Information: : Served as consultant/advisor for AbbVie, Amgen, Celgene, Genentech/Roche, GlycoMimetics, Jazz, Takeda, Tolero, and Treadwell; received travel support from AbbVie and Amgen; and received research funding to his institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, AROG, Celgene, Daiichi Sankyo, Esanex, F. Hoffmann‐La Roche, Forma, Genentech/Roche, GlycoMimetics, Hanmi, Incyte, Jazz, LP Therapeutics, Pfizer, Pharmacyclics, and Sigma Tau. B Jonas Funding Information: : Research funding from Cephalon Oncology; Advisory Board: Gilead. M Arellano Funding Information: : Research funding from AbbVie, Bristol‐Myers Squibb, Pfizer, SecuraBio, Glycomimetics, JW Pharmaceutical, Amgen, Novartis, Trovagene; advisory board member CVS Caremark. P Becker Funding Information: : Consultant for AbbVie, Genentech, F. Hoffman La‐Roche; advisory board member for F. Hoffman La‐Roche; holds shares from Reata Pharmaceuticals; honoraria from Amgen, Abbvie, Genentech; research funding from AbbVie, Genentech, Eli Lilly, Cellectis, Calithera, Stemline, Threshold, Flexus Biosciences, Novartis, Ablynx, and Agios. M Konopleva Funding Information: : Advisory role for AbbVie, Celgene, Novartis, Amgen, Servier; research funding from AbbVie, Celgene, and Servier; honoraria from AbbVie, Celgene, Novartis, Amgen, and Servier. AW is a former employee of the Walter and Eliza Hall Institute for Medical Research and eligible for royalty payments. A Wei Funding Information: : Research funding for clinical trials sponsored by AbbVie, Gilead Sciences, Janssen, Merck, Pharmacyclics, Syndax, TG Therapeutics, and Tolero. Consultancy/Advisory Board: AbbVie, AstraZeneca, Celgene, Janssen, Pharmacyclics, and Roche/Genentech. M Thirman Funding Information: : Data safety monitoring board for GlycoMimetics; research funding from AbbVie, Celgene, and Pfizer; advisory board member for Pfizer, Jazz, Takeda, Curis, Argenx, Agios, Servier, Celgene, and AbbVie. D Pollyea Funding Information: : Consultant for and research funding from AbbVie, TetraLogic, AstraZeneca, and Novartis. Co‐founder of Flash Therapeutics and Leap Oncology. A Letai ",
year = "2020",
doi = "10.1002/ajh.26039",
language = "English (US)",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
}